Señales en vivo de ALBO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mar 2023 @ 16:00):

Stats
Volumen de hoy	1.24M
Volumen promedio	566 901
Capitalización de mercado	915.89M
EPS	$0 ( 2023-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.63
ATR14	$0.932 (2.11%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Chiswell David	Sell	56 278	Common Stock
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	5 500	Stock Option (Right to Buy)

INSIDER POWER
-50.03
Last 100 transactions
Buy: 1 059 000 \| Sell: 2 762 067

Volumen Correlación

Largo: 0.36 (neutral)

Corto: 0.10 (neutral)

Signal:(68.034) Neutral

Albireo Pharma Inc Correlación

10 Correlaciones Más Positivas
WPRT	0.988
RESN	0.98
RXDX	0.977
RETA	0.972
CSII	0.965
PATI	0.963
VREX	0.963
ZGNX	0.962
FLMN	0.961
ADMS	0.96

10 Correlaciones Más Negativas
AAON	-0.975
EYE	-0.975
THRX	-0.969
IEP	-0.962
APLS	-0.96
PINC	-0.956
PEBK	-0.956
VRAR	-0.952
NVCT	-0.948
UNAM	-0.947

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Albireo Pharma Inc Correlación - Moneda/Commodity

0.73
( moderate )

0.03
( neutral )

0.48
( neutral )

0.45
( neutral )

-0.75
( moderate negative )

Albireo Pharma Inc Finanzas

Annual	2021
Ingresos:	$40.58M
Beneficio Bruto:	$39.22M (96.66 %)
EPS:	$-1.770

FY	2021
Ingresos:	$40.58M
Beneficio Bruto:	$39.22M (96.66 %)
EPS:	$-1.770

FY	2020
Ingresos:	$8.31M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-6.73

FY	2019
Ingresos:	$9.64M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-5.04

Financial Reports:

No articles found.

Albireo Pharma Inc

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.